Clinical trials: Active Psoriatic Arthritis
Active Juvenile Psoriatic Arthritis
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
- Trial name
- PEAPOD (NCT04804553)
- Testing
- Apremilast
- Where
- 44 sites in Belgium, France and 12 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic…
- Trial name
- IZAR-1 (NCT06641076)
- Testing
- Sonelokimab
- Where
- 182 sites in United States, Bulgaria and 18 more
- Volunteers
- 960 people
- Sponsor
- MoonLake Immunotherapeutics AG
Psoriatic Arthritis, Axial Spondyloarthritis
Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site
The purpose of this study was to demonstrate efficacy, including effects on inflammation by magnetic resonance imaging (MRI) assessments, of secukinumab on Achilles tendon enthesitis for up to 1 year with a primary focus at Week…
- Conditions
- Psoriatic Arthritis, Axial Spondyloarthritis, Enthesitis
- Trial name
- ACHILLES (NCT02771210)
- Testing
- Secukinumab
- Where
- 55 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Psoriatic Arthritis
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
- Trial name
- NCT06869551
- Testing
- Deucravacitinib
- Where
- 48 sites in United States, Brazil and 9 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis, Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
- Trial name
- NCT05855967
- Testing
- Ixekizumab
- Where
- 14 sites in India
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are…
- Trial name
- EXCEED 1 (NCT02745080)
- Testing
- Secukinumab, Adalimumab
- Where
- 156 sites in United States, Australia and 24 more
- Volunteers
- 853 people
- Sponsor
- Novartis Pharmaceuticals
Shear Wave Elastography
SWE to Detect Enthesitis in PsA: Relationship With SIRT2 Expression and Disease Activity
1. To assess the diagnostic utility of shear-wave elastography (SWE), gray-scale (GS) ultrasound, and Power Doppler (PD) in detecting Patellar and Achilles tendinopathy in psoriatic patients with and without arthritis. 2.
- Trial name
- NCT07188688
- Testing
- Musculoskeletal Ultrasound Device
- Where
- Egypt
- Volunteers
- 57 people
- Sponsor
- Assiut University
Arthritis, Psoriatic
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis
- Trial name
- NCT00646386
- Testing
- adalimumab
- Volunteers
- 315 people
- Sponsor
- Abbott
Psoriatic Arthritis
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
- Trial name
- NCT02376790
- Testing
- Etanercept, Methotrexate
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 851 people
- Sponsor
- Amgen
Arthritis, Psoriatic, Arthritis, Rheumatoid
Stepping Up For Inflammatory Arthritis
This study will examine the benefits of a monitored physical activity program for participants with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) using a wearable activity device (e.g.fitbit).
- Trial name
- SUFIA (NCT02912221)
- Testing
- Incentive
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- University of Pennsylvania
Arthritis, Psoriatic, Ultrasonography
Ultrasound in Psoriatic Arthritis Treatment
BACKGROUND Psoriatic arthritis (PsA) is a systemic inflammatory disease with articular and extra-articular features. Establishing the prognosis of a patient with PsA is hence important to define the treatment strategy.
- Conditions
- Arthritis, Psoriatic, Ultrasonography, Minimal Disease, Residual
- Trial name
- UPSTREAM (NCT03330769)
- Testing
- New course of treatment
- Where
- 4 sites in Italy
- Volunteers
- 250 people
- Sponsor
- University of Cagliari
Psoriatic Arthritis
Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
The purpose of this study was to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to…
- Trial name
- FUTURE5 (NCT02404350)
- Testing
- Secukinumab
- Where
- 172 sites in United States, Argentina and 26 more
- Volunteers
- 997 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic, Metabolic Syndrome
The DIET Trial - Dietetic Intervention in Psoriatic Arthritis
Psoriasis (Ps) and psoriatic arthritis (PsA) are associated with increased risk of metabolic syndrome (MetS), body fatness and cardiovascular risk.
- Trial name
- DIET (NCT03142503)
- Testing
- Diet + supplementation
- Volunteers
- 194 people
- Sponsor
- Federal University of São Paulo
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Arthritis, Psoriatic
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- Trial name
- APEX (NCT04882098)
- Testing
- Guselkumab
- Where
- 280 sites in United States, Australia and 27 more
- Volunteers
- 1,054 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Arthritis, Ankylosing Spondylitis
Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis
Background: Patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA) are more prone to physical inactivity but derive specific benefits from regular…
- Conditions
- Inflammatory Arthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- ImBAIA (NCT04426747)
- Testing
- No intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Fibromyalgia, Secondary
Fibromyalgia in Rheumatiod and Psoriatic Patients
the study based on investigate for fibromyalgia among rheumatiod arthritis patient and psoriatic arthritis.....and to what extent gibromyalgia affect disease activity indices ....and its relation to serum Vitamin D level in those…
- Trial name
- NCT04892602
- Testing
- Serum vitaminDlevel
- Where
- Egypt
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Sohag University
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
- Trial name
- NCT06668181
- Testing
- Bimekizumab
- Where
- 23 sites in Canada, France and 4 more
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL
Active Psoriatic Arthritis
Efficacy and Safety Study of SUNPG1623
This is a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of SUNPG1623
- Trial name
- NCT02980692
- Testing
- SUNPG1623 I, SUNPG1623 II, SUNPG1623 III
- Where
- United States
- Volunteers
- 391 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriatic Arthritis (PsA)
Psoriatic Arthritis Treat to Target vs. Usual Care
Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score <2.6), or as per their routine care.
- Trial name
- PRC-05-2011 (NCT01692912)
- Testing
- Intensive Care
- Where
- 4 sites in Canada
- Sponsor
- Pope Research Corporation